Myeloproliferative Neoplasms News

Clonal cytopenias of undetermined significance occurred more frequently than myelodysplastic syndrome in patients with cytopenias, suggesting they should be part of the diagnostic criteria for recognized blood cancers.

HemOnc Today and Infectious Disease News spoke with Thomas J. Walsh, MD, director of the Transplantation-Oncology Infectious Disease Program; chief of Infectious Diseases Translational Research Laboratory; professor of medicine, pediatrics, and microbiology and immunology; and the Henry Schueler Foundation Scholar in Mucormycosis at Weill Cornell Medicine of Cornell University, about the prevalence of rare infectious diseases in patients with cancer or HIV and how these diseases may complicate treatment. In this interview, Walsh discusses existing and emerging therapeutic options, and how the inherent nature of these infections makes research challenging.

Depression or symptoms of anxiety significantly compromised quality of life and physical function and worsened disease burden among patients with chronic graft-versus-host disease, according to findings presented at the BMT Tandem Meetings.

The rapidly rising costs of cancer care in the United States has created a considerable financial burden for many patients and their families. long

In 1971, President Nixon signed the National Cancer Act declaring a war against cancer, which transformed our ability to diagnose, treat and reduce morbidity and mortality from cancer.

Patients with polycythemia vera and a history of prior hydroxyurea use, phlebotomy requirements or palpable splenomegaly tended to have a significant disease-associated symptom burden, according to prospective study results published in Journal of Clinical Oncology.

Samuel M. Silver, MD, PhD, is professor in the department of internal medicine and director of the Cancer Center Network at University of Michigan Cancer Center, as well as chair of the National Comprehensive Cancer Network’s board of directors.

Caplacizumab induced a faster response time than placebo among patients with acquired thrombotic thrombocytopenic purpura, a rare blood-clotting disorder, according to phase 2 study results published in The New England Journal of Medicine.

The FDA has placed a full clinical hold on studies that involve pacritinib, an oral tyrosine kinase inhibitor in development for the treatment of patients with myelofibrosis.

Researchers in hematology have long believed that gene therapy may provide a pathway to more effectively treat chronic genetic hematologic disorders, with the potential for functional cures in certain cases.